Profile data is unavailable for this security.
About the company
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.
- Revenue in USD (TTM)11.16bn
- Net income in USD215.00m
- Incorporated2016
- Employees67.00k
- LocationIQVIA Holdings Inc4820 Emperor BlvdDURHAM 27703-8426United StatesUSA
- Phone+1 (919) 998-2000
- Fax+1 (302) 655-5049
- Websitehttps://www.iqvia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXACT Sciences Corporation | 1.06bn | -106.63m | 13.80bn | 4.11k | -- | 5.42 | -- | 13.00 | -0.7663 | -0.7663 | 7.77 | 16.98 | 0.3409 | 4.49 | 10.83 | 258,411.40 | -3.42 | -14.64 | -3.66 | -15.93 | 75.98 | 72.26 | -10.04 | -40.25 | 5.81 | -5.54 | 0.3775 | -- | 92.82 | 244.80 | 52.04 | -- | 70.67 | -- |
| Cardinal Health Inc | 153.59bn | -4.16bn | 14.41bn | 49.50k | -- | 11.98 | -- | 0.0938 | -14.04 | -14.04 | 519.75 | 4.12 | 3.75 | 11.53 | 18.18 | 3,102,748.00 | -10.14 | 2.60 | -24.91 | 6.02 | 4.53 | 5.16 | -2.71 | 0.7268 | 0.5286 | 7.55 | 0.8576 | 59.41 | 6.38 | 9.83 | 300.44 | 3.22 | 5.67 | 9.50 |
| Alnylam Pharmaceuticals, Inc. | 285.93m | -886.42m | 18.63bn | 1.32k | -- | 13.60 | -- | 65.15 | -8.03 | -8.03 | 2.59 | 11.93 | 0.1332 | 0.6982 | 5.23 | 216,124.00 | -41.29 | -35.69 | -46.58 | -39.36 | 87.75 | -- | -310.01 | -600.53 | 4.48 | -- | 0.00 | -- | 193.36 | 34.16 | -16.24 | -- | 32.78 | -- |
| AmerisourceBergen Corp. | 186.16bn | 1.58bn | 19.74bn | 22.00k | 12.78 | 5.50 | 9.76 | 0.106 | 7.59 | 7.59 | 886.85 | 17.66 | 4.60 | 16.11 | 12.97 | 8,461,793.00 | 3.94 | 2.11 | 16.50 | 8.73 | 2.78 | 2.78 | 0.8552 | 0.4435 | 0.6253 | 15.64 | 0.528 | 43.62 | 6.94 | 8.48 | -21.75 | 23.77 | 3.24 | 11.22 |
| Incyte Corporation | 2.23bn | -376.05m | 22.77bn | 1.46k | -- | 11.73 | -- | 10.21 | -1.74 | -1.74 | 10.24 | 8.93 | 0.8097 | 9.24 | 7.49 | 1,531,188.00 | -13.66 | 3.65 | -16.21 | 4.37 | 95.63 | 96.02 | -16.87 | 4.76 | 3.38 | -- | 0.0258 | 0.00 | 14.71 | 33.37 | 308.16 | -- | 22.87 | -- |
| BioMarin Pharmaceutical Inc. | 1.81bn | 114.01m | 22.80bn | 3.00k | 206.51 | 7.03 | 101.45 | 12.63 | 0.6104 | 0.6104 | 9.87 | 17.92 | 0.3943 | 0.6154 | 4.57 | 601,590.10 | 2.49 | -4.79 | 2.91 | -5.56 | 78.86 | 80.38 | 6.31 | -15.01 | 1.72 | -2.09 | 0.2101 | -- | 14.27 | 17.86 | 69.11 | -- | 6.90 | -- |
| McKesson Corporation | 231.05bn | 906.00m | 23.19bn | 80.00k | 28.50 | 4.55 | 11.32 | 0.1004 | 5.02 | 4.99 | 1,264.30 | 31.43 | 3.82 | 13.10 | 12.10 | 2,888,138.00 | 1.86 | 2.83 | 6.01 | 8.00 | 5.20 | 5.53 | 0.4873 | 0.7993 | 0.598 | 1.67 | 0.524 | 18.06 | 7.81 | 5.23 | 1,809.43 | -12.59 | -1.47 | 10.76 |
| Moderna Inc | 52.57m | -505.59m | 24.27bn | 830.00 | -- | 14.12 | -- | 461.72 | -1.50 | -1.50 | 0.1561 | 4.43 | 0.0271 | -- | 7.56 | 63,340.96 | -26.10 | -- | -28.25 | -- | -- | -- | -961.70 | -- | -- | -- | 0.0232 | -- | -55.42 | -- | -27.91 | -- | -- | -- |
| Iqvia Holdings Inc | 11.16bn | 215.00m | 27.25bn | 67.00k | 131.42 | 4.92 | 18.46 | 2.44 | 1.09 | 1.09 | 56.33 | 29.02 | 0.4832 | -- | 4.38 | 166,537.30 | 1.10 | 1.50 | 1.32 | 1.83 | 33.89 | 33.19 | 2.27 | 2.88 | -- | 1.93 | 0.6757 | 0.00 | 6.49 | 15.22 | -14.73 | -11.73 | 47.75 | -- |
| Seattle Genetics, Inc. | 956.03m | -313.72m | 30.18bn | 1.61k | -- | 17.05 | -- | 31.57 | -1.86 | -1.86 | 5.68 | 10.23 | 0.519 | 0.83 | 5.01 | 595,656.10 | -17.03 | -14.09 | -19.49 | -16.76 | 93.40 | 90.52 | -32.82 | -27.33 | 4.18 | -8.10 | 0.00 | -- | 40.02 | 26.17 | 28.76 | -- | 32.73 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2020 | 18.88m | 9.89% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 8.77m | 4.60% |
| SSgA Funds Management, Inc.as of 31 Mar 2020 | 7.94m | 4.16% |
| Longview Partners LLPas of 31 Mar 2020 | 6.88m | 3.61% |
| Jackson Square Partners LLCas of 31 Mar 2020 | 5.10m | 2.67% |
| AllianceBernstein LPas of 31 Mar 2020 | 4.90m | 2.57% |
| Janus Capital Management LLCas of 31 Mar 2020 | 4.03m | 2.11% |
| Farallon Capital Management LLCas of 31 Mar 2020 | 3.74m | 1.96% |
| Steadfast Capital Management LPas of 31 Mar 2020 | 2.85m | 1.49% |
| Lazard Asset Management LLCas of 31 Mar 2020 | 2.85m | 1.49% |
